# OnCo record telik (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/telik/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "telik" ;
  schema:name "Telik"@en ;
  schema:alternateName "Telik, Inc."@en ;
  schema:description "Telik was a Palo Alto biotech whose glutathione analogue canfosfamide (Telcyta) failed its phase 3 trials in ovarian and lung cancer in the 2000s, a reminder that late-stage failure is the norm in oncology."@en ;
  schema:url <https://onco.cc/companies/telik/>, <http://telik.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <http://telik.com>, <https://clinicaltrials.gov/search?lead=Telik%2C%20Inc.>, <https://www.wikidata.org/wiki/Q17146330> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:terms <https://onco.cc/terms/pivotal-trial/>, <https://onco.cc/terms/clinical-trial/> .